Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.2 to v3.6.3, indicating a minor update to the page. No substantive study content appears to be changed.
    Difference
    0.1%
    Check dated 2026-07-04T01:07:54.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.0 to v3.6.2, signaling a small maintenance update to the ClinicalTrials.gov study page rather than a substantive content change.
    Difference
    0.1%
    Check dated 2026-06-26T23:15:40.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page now presents new guidance/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and a 'No longer looking for participants' notice. The Intervention/Treatment heading has been updated and the older 'Intervention / Treatment' label removed, alongside a new revision indicator 'Revision: v3.6.0' replacing the previous version.
    Difference
    0.4%
    Check dated 2026-06-12T14:08:30.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page's revision tag has been updated from v3.5.4 to v3.5.5, representing a new build of the ClinicalTrials.gov page. It indicates an update to the site software rather than changes to the study information presented on the page.
    Difference
    0.1%
    Check dated 2026-06-05T10:07:11.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The page adds a new site revision tag for v3.5.4 and removes the previous v3.5.3 label, signaling a small platform update in the release notes area rather than changes to the study information.
    Difference
    0.1%
    Check dated 2026-05-15T02:16:05.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page now displays a new revision tag (v3.5.3), replacing the previous v3.5.2, indicating a release update to the page's content management without altering study data. No study details or eligibility criteria appear to be changed.
    Difference
    0.1%
    Check dated 2026-04-30T18:41:22.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.